| Ytd | -24.87% | |
| 1y | -28.83% |
| Open | 5.95 | Prev Close | 5.80 | Low | 5.80 | High | 5.95 | Mkt Cap | 7.15M |
| Vol | 17.00 | Avg Vol | 2.64K | EPS | -6.30 | P/E | -0.92 | Forward P/E | -159.83 |
| Beta | 1.50 | Short Ratio | 0.14 | Inst. Own | 0.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-01 | 50-d Avg | 5.99 | 200-d Avg | 7.16 | 1yr Est | 30.00 |
ADXN News
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript
Addex Therapeutics (NASDAQ:ADXN) reported first-quarter financial results on Thursday. The transcrip
Companies Reporting Before The Bell • TD Synnex (NYSE:SNX) is projected to report quarterly earnings
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.53) per share. This is a 15.04 per
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage bio
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (S
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.50) per share. This is a 9.49 perc
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive a
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics
Addex Therapeutics Ltd. Sponsored ADR (NASDAQ: ADXN - Get Free Report) saw a large decrease in short
Addex Therapeutics Ltd. Sponsored ADR (NASDAQ: ADXN - Get Free Report) was the target of a large gro
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutic
Aditxt (NASDAQ: ADTX - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeuti
Up to $3,300,000American Depositary Shares Representing Ordinary SharesWe have entered into an At T
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.50) per share. This is a 45.85 per
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutic
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2025 Earnings Call October 1, 2025 10:00 AM EDT Company Par
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(2.90) per share. This is a 127.37 pe
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated ro
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage bi
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeut
